HXE
Viewing r1 — May 7, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
HXE (hydroxetamine) is a synthetic dissociative of the arylcyclohexylamine class. It is the primary metabolite of methoxetamine, and roughly twice as potent at the NMDA.[1] It blocks glutamate signaling in the brain, producing the disconnection from body and environment characteristic of dissociative drugs.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
ketamine, methoxetamine, PCP +2 moreketamine, methoxetamine, PCP, dextromethorphan, deschloroketamine show less
HXE was first identified in 2013 as a breakdown product of Methoxetamine, not as a drug in its own right.[2] Progressive international scheduling of MXE created a market vacuum that HXE filled when it appeared as a standalone substance in late 2019. It now circulates on unregulated markets and has been linked to deaths since 2021,[3] with drug monitoring agencies actively tracking it.
Subjective effects include dissociation, pain suppression, warmth, derealization, and visual distortion. The experience has a sedating, enveloping quality — lower doses bring mild stimulation and perceptual softening, while higher doses produce deep immersive internal states where the surroundings largely disappear. Confusion, impaired coordination, and a compulsive compulsive redosing urge are common unwanted effects.
Dependence liability is moderate, inferred from ketamine-class data; no lethal dose has been established in any species. The greatest danger comes from combinations — mixing with stimulants has proven fatal in the class, and adding depressants amplifies sedation and respiratory depression. HXE is among the least-studied dissociatives in active use — one electrophysiological study and forensic case reports make up its entire evidence base.
History[edit]
Discovery
HXE — formally O-desmethylmethoxetamine — was first identified in 2013 as the primary urinary metabolite of methoxetamine, not as a drug.[2][4] Multiple labs confirmed the structure and independently synthesized it as a forensic reference standard.[5]
The methoxetamine wave
MXE rose to prominence around 2010 as one of the most widely used dissociative designer drugs of that decade.[6][4] International scheduling followed — the UK in 2013,[7] the US in 2022[8]}. That successive prohibition created the market opening HXE would fill.
Market entry
HXE appeared as a standalone substance in late 2019,[9] part of a pattern in which metabolites of scheduled dissociatives are repurposed as primary drugs.[10] The first confirmed toxicology case was documented in November 2021,[3] and French surveillance networks now track it as an emerging ketamine-structural analog.[11]
The name "hydroxetamine" blends "hydroxy" — the chemical group that distinguishes HXE from MXE — with the "-etamine" suffix of ketamine-derived naming. HXE parallels MXE as an abbreviation. In user communities, HXE's identity is tied to being a metabolite that turned out to be active on its own — a substance documented by forensic chemists before anyone thought to take it deliberately.
Chemistry[edit]
Structural class
HXE belongs to the arylcyclohexylamine family — the same structural class as ketamine and methoxetamine. It is the O-demethylation product of MXE: where MXE carries a methoxy group on the phenyl ring, HXE carries a hydroxyl group at the same position. This single substitution is also the transformation the body performs when it metabolizes MXE.
Molecular identity
| Molecular formula | C₁₄H₁₉NO₂ |
| Molecular weight | 233.31 g/mol |
No published data exist on HXE's melting point, solubility, or storage stability. The hydroxyl group at the 3-position is expected to make it more water-soluble than MXE and provides a site the body uses during metabolism.inferred
Pharmacology[edit]
Mechanism of action
HXE blocks the NMDA — the brain's main glutamate channel — at the same site as ketamine. It is roughly twice as potent as MXE at this receptor,[1] meaning the dissociative threshold is reached at lower concentrations than with ketamine or MXE.
Beyond NMDA blockade, HXE likely engages opioid receptors[12][13][14] and serotonin systems,[15][16] and stimulates dopamine release in reward circuits[6] — all inferred from its parent compound MXE. None of this has been confirmed for HXE directly.inferred
Pharmacokinetics
No human pharmacokinetic study exists for HXE taken directly. What is known comes from its role as MXE's metabolite — it forms when the body removes MXE's methoxy group,[2] reaching peak brain concentrations in rats at 30 minutes with strong penetration into the nervous system.[4] When taken as a primary drug, its breakdown is expected to follow pathways analogous to structurally related compounds.[17]
Neuroscience[edit]
Where it acts
HXE disrupts the thalamocortical relay — the brain system that integrates sensory input into unified conscious experience.[14] Blocking glutamate receptors here produces the characteristic disconnection from body and surroundings. Given HXE's potency at this receptor,[1] this disconnection threshold is reached at lower concentrations than with ketamine or MXE.
Why it matters
NMDA blockade also releases dopamine in the brain's reward system,[6] driving the reinforcing pull and potential for compulsive use. The same mechanism can trigger rapid structural changes in brain connections — the pathway behind ketamine's fast antidepressant effect.[14] Whether this applies to HXE has not been tested.
Key unknowns: whether HXE's greater NMDA potency produces greater neuroplastic effects than ketamine, whether its two enantiomers differ in neural activity as they do for ketamine, and whether opioid receptor engagement meaningfully shapes its profile. No neuroimaging or electrophysiological studies have been conducted with HXE in any species.
Subjective Effects[edit]
HXE produces a warm, enveloping dissociation with a notable analgesic quality. The experience is inward and sedating rather than stimulating — the defining character is quieting. Body awareness softens and recedes; the outside world fades while internal states become more vivid.
Relative to ketamine, HXE is longer-lasting and more immersive at equivalent dissociative depth. Compared to its parent compound methoxetamine, it is qualitatively similar but roughly twice as potent at the NMDA,[1] meaning similar effects arrive at proportionally lower doses.
Effect Grid
A clear dissociative state establishes itself — pronounced derealization and depersonalization create a sense of observing experience from a comfortable distance. Cognitive euphoria is prominent, accompanied by introspective depth and immersion enhancement. Visual processing suppression and spatial disorientation become obvious, and internal focus deepens substantially.
Analgesic effects are now clearly apparent, with significant touch suppression and pain suppression. Motor control impairment is meaningful — walking requires deliberate effort and coordination is noticeably degraded. Sedation predominates over stimulation at this level. Dizziness and mild nausea may occur, particularly during the come-up.
Memory suppression begins to affect recall of the experience. Time alteration distorts the subjective passage of time. This tier represents the core dissociative experience for most users — deeply introspective and perceptually altered, but with retained awareness of external surroundings.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual acuity suppression · Perspective distortion · Depth perception distortion · Auditory distortion · Vestibular distortion · Ganzfeld effect · Dreaming enhancement · Music enhancement · Visual drifting · Auditory misinterpretation · Sensory deprivation · Visual haze / noise · Auditory suppression · Brightness alteration · Color alteration · Geometry · Auditory enhancement · Light sensitivity · Peripheral misidentification · Peripheral vision distortion · Sound sensitivity · Tracers · Visual breathing · Visual morphing · Holotropic state · After-images · Tinnitus · Visual processing suppression · Internal hallucinations · Environmental orbism / cubism · External hallucinations · Visual scenery slicing · Auditory hallucinations · Object transformations · Perspective hallucinations
Vestibular distortion · Ganzfeld effect · Dreaming enhancement · Music enhancement · Visual drifting · Auditory misinterpretation · Sensory deprivation · Visual haze / noise · Auditory suppression · Brightness alteration · Color alteration · Geometry · Auditory enhancement · Light sensitivity · Peripheral misidentification · Peripheral vision distortion · Sound sensitivity · Tracers · Visual breathing · Visual morphing · Holotropic state · After-images · Tinnitus · Visual processing suppression · Internal hallucinations · Environmental orbism / cubism · External hallucinations · Visual scenery slicing · Auditory hallucinations · Object transformations · Perspective hallucinations
Nystagmus (eye wobbles) · Sedation · Bodily heaviness · Body schema distortion · Muscle relaxation · Physical fatigue · Spontaneous body sensations · Nausea · Bodily pressures · Sexual arousal suppression · Appetite suppression · Breathing alteration · Dry mouth · Heart rate perception changes · Laughter fits · Nasal congestion · Pupil dilation · Tactile euphoria · Tingling / electric sensations · Stimulation · Bodily lightness · Headache · Insomnia · Salivation · Vasoconstriction · Vibrations / buzzing · Constipation · Trembling · Vomiting · Watery eyes · Yawning · Bodily dissociation · Tactile hallucination · Phantom limb sensations
Body schema distortion · Muscle relaxation · Physical fatigue · Spontaneous body sensations · Nausea · Bodily pressures · Sexual arousal suppression · Appetite suppression · Breathing alteration · Dry mouth · Heart rate perception changes · Laughter fits · Nasal congestion · Pupil dilation · Tactile euphoria · Tingling / electric sensations · Stimulation · Bodily lightness · Headache · Insomnia · Salivation · Vibrations / buzzing · Constipation · Trembling · Vomiting · Watery eyes · Yawning · Bodily dissociation · Tactile hallucination · Phantom limb sensations
Immersion enhancement · Analysis suppression · Thought deceleration · Cognitive fatigue · Confusion · Focus suppression · Information processing suppression · Memory fragmentation · Thought disorganization · Pattern recognition suppression · Conceptual thinking · Introspection enhancement · Language suppression · Motivation suppression · Suggestibility enhancement · Thought loops · Creativity enhancement · Humor enhancement · Aesthetic enhancement · Delusions of sobriety · Multiple thought streams · Novelty enhancement · Openness enhancement · Cognitive dysphoria · Amnesia · Delirium · Delusions
Cognitive fatigue · Confusion · Focus suppression · Information processing suppression · Memory fragmentation · Thought disorganization · Pattern recognition suppression · Conceptual thinking · Introspection enhancement · Language suppression · Motivation suppression · Thought loops · Creativity enhancement · Humor enhancement · Aesthetic enhancement · Delusions of sobriety · Multiple thought streams · Novelty enhancement · Openness enhancement · Cognitive dysphoria · Amnesia · Delirium · Delusions
Emotional suppression · Anxiety · Catharsis · Emotional enhancement · Empathy suppression · Dysphoria
Empathy suppression · Dysphoria
Communication suppression · Social disconnection · Craving · Sociability suppression · Flow state · Sociability enhancement · Cognitive disconnection · Boundary dissolution · Identity alteration · Ego dissolution
Flow state · Sociability enhancement · Cognitive disconnection · Boundary dissolution · Identity alteration · Ego dissolution
Time cessation
Non-dual awareness · Transpersonal feelings · Transpersonal visions · Voidness · Near-death experience · Death-rebirth sequence
Near-death experience · Death-rebirth sequence
Timeline
Initial awareness of altered state — subtle bodily lightness, mild proprioceptive shift, faint mood elevation. Effects may be ambiguous to inexperienced users.
Progressive dissociation builds steadily. Warm body high emerges, cognitive effects develop — thought deceleration, initial derealization. Nausea most likely during this phase.
Full dissociative state with maximum cognitive disconnection, derealization, and perceptual alteration. Analgesic warmth prominent. Motor control significantly impaired.
Gradual return of external awareness and bodily sensation. Residual dissociation persists — spatial disorientation and cognitive fog linger. Drowsiness often increases as resolution progresses.
Residual cognitive effects, mild mood alteration, and physical fatigue. Some users report a contemplative afterglow with subtle emotional warmth.
⚠ Do not drive or operate heavy machinery for at least 12 hours after oral HXE use.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- moderate
- Tolerance reset
- 1.5 weeks
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- ketamine · methoxetamine · PCP
Toxicity
Acute toxicity
No lethal dose or controlled toxicity data exist for HXE in any species. Deaths have been documented since November 2021,[3] though no peer-reviewed case report specific to HXE has been published.safety citation needed
The closest reference point is MXE. A fatal MXE-amphetamine combination produced deep coma, breathing failure, dangerous overheating, seizures, and multi-organ failure — at MXE blood levels within the typical range, suggesting the combination drove the lethal outcome.[18]
Neurological toxicity
MXE has caused loss of coordination, involuntary eye movement, and slurred speech,[19] as well as seizures and dangerously low blood sodium.[20] HXE has not been studied directly, but the shared mechanism makes these plausible risks.inferred
Urological toxicity
Chronic ketamine-class use causes progressive bladder damage — urinary urgency, pain, reduced capacity, and in severe cases kidney damage.[21][22][23][24] MXE was marketed as bladder-friendly, but no evidence supports this claim for MXE or HXE. The risk with chronic HXE use has not been studied.safety citation needed
Psychological risks
High doses can produce paranoia, confusion, and thought disorganization — a property NMDA antagonists share across the class.[14] Depersonalization and derealization, while characteristic of dissociatives, can become distressing or destabilizing in vulnerable individuals.
A compulsive compulsive redosing urge is a recognized pattern with NMDA antagonists, driven by dopamine release in reward pathways.[6]citation needed
Tolerance & dependence
Tolerance builds with repeated use through receptor-level adaptation.[14] Cross-tolerance with other dissociatives — Ketamine, methoxetamine, dextromethorphan — is expected from the shared mechanism.
Ketamine dependence is documented clinically, characterized by craving and dose escalation without a prominent physical withdrawal.[25] MXE shows abuse potential through dopamine stimulation.[6] HXE's moderate dependence classification is inferred from class data, not substance-specific evidence.safety citation needed
Drug interactions
Stimulants carry the strongest documented risk. A fatal MXE-amphetamine combination produced overheating, muscle breakdown, and organ failure at typical MXE blood levels — combining NMDA antagonists with stimulants can be lethal.[18]
Depressants (alcohol, benzodiazepines, opioids) add to HXE's own sedative effects and suppress breathing further.
MAOIs pose a serotonin syndrome risk — a potentially life-threatening overheating and seizure response — given MXE's demonstrated SERT activity.[15][16]
Other NMDA antagonists (Ketamine, dextromethorphan, deschloroketamine) produce additive dissociation with unpredictable intensification.
CYP3A4 and CYP2B6 inhibitors may slow HXE clearance based on MXE's metabolic pathways,[2] prolonging or intensifying effects.safety citation needed
Contraindications
No substance-specific data exist. The following are inferred from ketamine and MXE class pharmacologyinferred:
Liver or kidney impairment: Fatal MXE cases involved multi-organ failure.[18]
Bladder or urinary tract conditions: Chronic ketamine-class use causes progressive bladder damage.[21][22]
Personal or family history of psychotic disorders: NMDA antagonists can trigger or worsen psychotic episodes.[14]
Heart conditions: Ketamine-class compounds raise heart rate and blood pressure.safety citation needed
Concurrent MAOI use: Serotonin syndrome risk from potential serotonin transporter engagement.[15]
Pregnancy: NMDA receptor signaling is critical for fetal brain development; use during pregnancy is contraindicated as a precaution.safety citation needed
Harm Reduction[edit]
Forms & Identification
HXE appears as a white to off-white crystalline powder. Because it circulates exclusively through unregulated markets, there is no quality control on what is sold as HXE.
Reagent testing can help distinguish arylcyclohexylamines from other substance classes but cannot differentiate between specific compounds within the class. Laboratory drug checking is the only reliable method to confirm identity and purity.
The potency difference between HXE and visually identical dissociative powders means dosing assumptions from one substance cannot be transferred to another. Treat every new batch as unknown until tested.
Guidelines
- Test every batch with reagent kits before use; consider laboratory analysis for confirmation
- Start with a low dose and wait for full onset before considering redosing — HXE's onset can be gradual, particularly by oral route
- Have a sober sitter present, especially at higher doses or with unfamiliar batches
- Use a scale accurate to the milligram — volumetric dosing for solutions is preferable to eyeballing powder
- Do not drive or operate machinery for at least 12 hours after use
- Prepare water, blankets, and a comfortable space before dosing
- If using insufflation, alternate nostrils and rinse nasal passages afterward
Set & Setting
Dissociative experiences are strongly shaped by environment and mental state. A familiar, physically safe, low-stimulation environment reduces the risk of disorientation and injury.
A sober, trusted companion who can monitor for distress and physical danger is essential. A dissociated person may not recognize when help is needed.
Avoid environments with fall hazards, water, traffic, or other physical dangers. Cognitive impairment and loss of coordination are expected, not exceptional.
Aftercare & integration. The dissociative afterglow can persist for hours to days. During this period, judgment and coordination may remain subtly impaired even after primary effects have subsided. Avoid important decisions, driving, and demanding physical activity until fully baseline.
Dissociative experiences — particularly deep or unexpected ones — can leave residual derealization. Grounding techniques such as physical contact with textured objects, cold water on the face, or structured breathing help re-establish ordinary awareness. Persistent depersonalization or derealization beyond 48 hours warrants professional support.
Recovery & Support
Compulsive redosing and escalating use are recognized risks with NMDA antagonists. If HXE use has become difficult to control, or if tolerance has led to dose escalation, professional support is appropriate. Ketamine-specific treatment resources are the most relevant framework, as no HXE-specific treatment literature exists.
Urinary symptoms — frequency, urgency, pain — developing during a period of regular use should prompt immediate medical evaluation and cessation. Ketamine-associated bladder damage is progressive but partially reversible if caught early.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Seek immediate help if the person shows seizures, loss of consciousness, extremely slow or stopped breathing, blue or grey lips, chest pain, body temperature hot to the touch, or violent and self-harming behavior. Confusion and immobility are expected at high dissociative doses — unresponsiveness to pain, abnormal breathing, or vomiting while unconscious are not.
Immediate steps:
- 1. Call emergency services immediately
- 2. Place the person in the recovery position (on their side) to prevent choking if vomiting occurs
- 3. Do not leave them alone
- 4. Do not restrain them unless they are in immediate physical danger
- 5. Monitor breathing continuously until help arrives
- 6. Do not induce vomiting
What to tell the dispatcher: Name the substance (HXE, hydroxetamine, arylcyclohexylamine dissociative), the amount taken if known, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from prosecution when reporting a drug emergency.
Legal Status[edit]
HXE is not explicitly scheduled in most countries but falls within the scope of structural analog laws, arylcyclohexylamine catch-all definitions, and blanket new psychoactive substance controls in several key jurisdictions.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not explicitly scheduled (federal) | Not listed in the Controlled Substances Act. The Federal Analogue Act (21 U.S.C. § 813) may apply — HXE is structurally and pharmacologically similar to Schedule I MXE (scheduled July 2022[8]) and Schedule III ketamine. Application requires case-by-case legal determination.[3] |
| United Kingdom | Likely Class B (Misuse of Drugs Act 1971) | The generic arylcyclohexylamine definition captures compounds derived from 2-amino-2-phenylcyclohexanone by nitrogen or phenyl ring substitution — HXE fits this definition. Additionally subject to the Psychoactive Substances Act 2016.[7] |
| France | Likely controlled | MXE classified as stupéfiant in August 2013. HXE under active addictovigilance surveillance as an emerging ketamine-analogue NPS.[11] |
| Germany | Controlled (NpSG) | MXE controlled July 2013. The Neue-psychoaktive-Stoffe-Gesetz (2016) broadly prohibits NPS including arylcyclohexylamine derivatives. |
| Netherlands | Unclear; likely controlled | MXE placed on Opiumwet List I in July 2015. HXE status not explicitly determined. |
| Canada | Unclear; MXE Schedule I | MXE classified as Schedule I (January 2011). HXE identified in at least one Canadian toxicology case since November 2021.[3] |
| Australia | Not explicitly scheduled | No specific scheduling identified. Class-level controls via ketamine analog provisions may apply. |
Analogue act considerations
In the US, the Federal Analogue Act may apply — HXE is structurally similar to Schedule I MXE and more potent at the same receptor,[1] though application requires case-by-case determination.[3] In the UK, the generic arylcyclohexylamine catch-all unambiguously captures HXE.[7]
Legal status varies by jurisdiction and changes frequently. This information is not legal advice. Verify current local laws before acting on this information.
references
- [1]
- [2] ^abcdMeyer MR, Bach M, Welter J, Bovens M, Turcant A, Maurer HH (2013) Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn — Analytical and Bioanalytical Chemistry doi:10.1007/s00216-013-7051-6
- [3]
- [4] ^abcHorsley RR, Lhotkova E, Hajkova K, Jurasek B, Kuchar M, Palenicek T (2016) Detailed pharmacological evaluation of methoxetamine (MXE), a novel psychoactive ketamine analogue-Behavioural, pharmacokinetic and metabolic studies in the Wistar rat — Brain Research Bulletin doi:10.1016/j.brainresbull.2016.05.002
- [5] ^Hajkova K, Jurasek B, Sykora D, Palenicek T, Miksatkova P, Kuchar M (2016) Salting-out-assisted liquid-liquid extraction as a suitable approach for determination of methoxetamine in large sets of tissue samples — Analytical and Bioanalytical Chemistry doi:10.1007/s00216-015-9221-1
- [6]